Maximilian Marhold (M Marhold)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 9

Top Venues

Medizinische Universität Wien (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Medizinische Universität Wien - Dec 07 2016

Austria

PHD

Publications

Eva Welsch, Eva Schuster, Michael Krainer, Maximilian Marhold, Rupert Bartsch, Michael B Fischer, Michael Hermann, Gabriele Hastermann, Heidemarie Uher, Gerhard Sliutz, Birgit Anker, Robert Zeillinger, Eva Obermayr
Comparison of RNA Marker Panels for Circulating Tumor Cells and Evaluation of Their Prognostic Relevance in Breast Cancer. Cancers 15 (4) (2023)
Eva Welsch, Eva Schuster, Michael Krainer, Maximilian Marhold, Rupert Bartsch, Michael B Fischer, Michael Hermann, Gabriele Hastermann, Heidemarie Uher, Gerhard Sliutz, Birgit Anker, Robert Zeillinger, Eva Obermayr
Comparison of RNA Marker Panels for Circulating Tumor Cells and Evaluation of Their Prognostic Relevance in Breast Cancer. Cancers 15 (4) (2023)
Eva Welsch, Eva Schuster, Michael Krainer, Maximilian Marhold, Rupert Bartsch, Michael B Fischer, Michael Hermann, Gabriele Hastermann, Heidemarie Uher, Gerhard Sliutz, Birgit Anker, Robert Zeillinger, Eva Obermayr
Comparison of RNA Marker Panels for Circulating Tumor Cells and Evaluation of Their Prognostic Relevance in Breast Cancer. Cancers 15 (4) (2023)
Rupert Bartsch, Anna Sophie Berghoff, Julia Furtner, Maximilian Marhold, Elisabeth Sophie Bergen, Sophie Roider-Schur, Angelika Martina Starzer, Heidrun Forstner, Beate Rottenmanner, Karin Dieckmann, Zsuzsanna Bago-Horvath, Helmuth Haslacher, Georg Widhalm, Aysegül Ilhan-Mutlu, Christoph Minichsdorfer, Thorsten Fuereder, Thomas Szekeres, Leopold Oehler, Birgit Gruenberger, Christian F Singer, Ansgar Weltermann, Rainer Puhr, Matthias Preusser
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nature medicine 28 (9) (2022)
Maximilian Marhold, Simon Udovica, Thais Topakian, Peter Horak, Reinhard Horvat, Erwin Tomasich, Gerwin Heller, Michael Krainer
MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice. Cancers 14 (3) (2022)
Christina Steinbach, Almas Merchant, Alexandru-Teodor Zaharie, Peter Horak, Maximilian Marhold, Michael Krainer
Current Developments in Cellular Therapy for Castration Resistant Prostate Cancer: A Systematic Review of Clinical Studies. Cancers 14 (22) (2022)
Maximilian Marhold
Hormonal control of cancer: an outdated topic? ESMO open 5 (4) (2021)
Andreas Heinzel, Maximilian Marhold, Paul Mayer, Michael Schwarz, Erwin Tomasich, Arno Lukas, Michael Krainer, Paul Perco
Synthetic lethality guiding selection of drug combinations in ovarian cancer. PloS one 14 (1) (2019)
H Taghizadeh, Maximilian Marhold, E Tomasich, S Udovica, A Merchant, Michael Krainer
Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives. Oncoimmunology 8 (11) (2019)

Maximilian Marhold.css-eqlu8i{font-size:small;padding-left:4px;} (M Marhold)

Publication Activity (10 Years)

Top Topics

Top Venues

Maximilian Marhold (M Marhold)